Suppr超能文献

通过涉及 CDK1 的途径研究达昔利布诱导淋巴瘤 Raji 细胞凋亡和细胞周期停滞的机制。

Study of the mechanism by which dinaciclib induces apoptosis and cell cycle arrest of lymphoma Raji cells through a CDK1-involved pathway.

机构信息

Department of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.

Department of Pathology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.

出版信息

Cancer Med. 2019 Aug;8(9):4348-4358. doi: 10.1002/cam4.2324. Epub 2019 Jun 17.

Abstract

OBJECTIVE

This study aimed to identify and evaluate the mechanism by which apoptosis and cell cycle arrest were induced by dinaciclib in lymphoma Raji cells.

METHODS

The colony formation assay was used to detect cell proliferation of Raji cells. Cell cycle arrest and cell apoptosis were determined by flow cytometry and TUNEL assays, respectively. Protein expression related to the Raji cell state was evaluated by Western blot. The Raji/Dinaciclib drug-resistant cell line was established, where the regulating functions of CDK1-involved pathway were verified. In addition, the effect of dinaciclib in vivo was examined in orthotopically implanted tumors in nude mice.

RESULTS

Cell apoptosis was induced, and DNA synthesis ability was decreased in a time-dependent manner in dinaciclib-treated lymphoma Raji cells. Furthermore, the cell cycle was found to be blocked in the G2/M Phase. Further study indicated that CDK1-involved pathway played a key regulatory role in this process. It was revealed by cell transfection that the expression of cell cycle proteins was downregulated after treatment with dinaciclib through a CDK1-involved pathway, which eventually led to apoptosis. Knockdown of CDK1 restored the sensitivity of the Raji/Dinaciclib cells to dinaciclib. Xenograft model of nude mice showed that dinaciclib treatment in vivo could effectively inhibit tumor growth, consistent with the experiment results mentioned before.

CONCLUSION

In this study, we clarified the mechanisms through which dinaciclib induces Raji cell apoptosis and blocks the cell cycle through a CDK1-involved pathway, which supported that dinaciclib had potential values in the treatment of lymphoma.

摘要

目的

本研究旨在鉴定和评估达昔昔布诱导淋巴瘤 Raji 细胞凋亡和细胞周期停滞的机制。

方法

采用集落形成实验检测 Raji 细胞的增殖能力。通过流式细胞术和 TUNEL 实验检测细胞周期停滞和细胞凋亡。采用 Western blot 检测与 Raji 细胞状态相关的蛋白表达。建立 Raji/达昔昔布耐药细胞系,验证 CDK1 通路相关调节功能。此外,在裸鼠原位移植瘤模型中考察达昔昔布的体内作用。

结果

达昔昔布处理的淋巴瘤 Raji 细胞诱导细胞凋亡,DNA 合成能力呈时间依赖性下降。此外,细胞周期被阻滞在 G2/M 期。进一步研究表明,CDK1 通路在这一过程中起关键调节作用。通过细胞转染发现,达昔昔布通过 CDK1 通路下调细胞周期蛋白的表达,导致细胞凋亡。CDK1 敲低恢复了 Raji/Dinaciclib 细胞对达昔昔布的敏感性。裸鼠异种移植模型显示,达昔昔布体内治疗可有效抑制肿瘤生长,与前文所述实验结果一致。

结论

本研究阐明了达昔昔布通过 CDK1 通路诱导 Raji 细胞凋亡和阻滞细胞周期的机制,表明达昔昔布在淋巴瘤治疗中具有潜在价值。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fc69/6675732/ad538ddf742f/CAM4-8-4348-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验